ARBs and myocardial infarction

Medical Letter on Drugs and Therapeutics

Volumn 47, Issue 1208, 2005, Pages 38-39

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; IRBESARTAN; LOSARTAN POTASSIUM; OLMESARTAN; PLACEBO; TELMISARTAN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR;

ABSENCE OF SIDE EFFECTS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; MORTALITY; SHORT SURVEY; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; RISK FACTOR; STANDARD;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONTROLLED CLINICAL TRIALS; HYPERTENSION; MYOCARDIAL INFARCTION; RECEPTOR, ANGIOTENSIN, TYPE 1; RISK FACTORS;

EID: 18444394899     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. S Verma and M Strauss. Angiotensin receptor blockers and myocardial infarction. BMJ 2004; 329:1248.
2. BI Levy. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004; 109:8.
3. S Julius et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022.
4. B Dahlöf et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study [LIFE]: a randomised trial against atenolol. Lancet 2002; 359:995.
5. H Lithell et al. The study on cognition and prognosis in the elderly [SCOPE]: principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875.
6. B Pitt et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582.
7. K Dickstein et al. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360:752.
8. MA Pfeffer et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both [VALIANT]; N Engl J Med 2003; 349:1893.
9. MA Pfeffer et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362:759.
10. CB Granger et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772.